These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18827173)

  • 1. Comment: tigecycline for the treatment of Acinetobacter infections: a case series.
    Curcio D
    Ann Pharmacother; 2008 Nov; 42(11):1717-8; author reply 1718. PubMed ID: 18827173
    [No Abstract]   [Full Text] [Related]  

  • 2. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective.
    Curcio D; Fernández F
    J Antimicrob Chemother; 2007 Aug; 60(2):449-50. PubMed ID: 17561503
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia.
    Chang YY; Liu YM; Liu CP; Kuo SC; Chen TL;
    J Microbiol Immunol Infect; 2018 Feb; 51(1):148-152. PubMed ID: 29050749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline for the treatment of Acinetobacter infections: a case series.
    Gallagher JC; Rouse HM
    Ann Pharmacother; 2008 Sep; 42(9):1188-94. PubMed ID: 18614749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea.
    Park YK; Choi JY; Song JH; Ko KS
    Int J Antimicrob Agents; 2009 Mar; 33(3):289-90. PubMed ID: 19091518
    [No Abstract]   [Full Text] [Related]  

  • 6. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.
    Curcio D; Fernández F; Jones RN; Ferraro MJ; Reller LB; Schreckenberger PC; Sader HS
    J Clin Microbiol; 2007 Jun; 45(6):2095; author reply 2095-6. PubMed ID: 17548459
    [No Abstract]   [Full Text] [Related]  

  • 7. The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used.
    Zárate MS; Serruto G; Smayevsky J
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e351-2. PubMed ID: 20031463
    [No Abstract]   [Full Text] [Related]  

  • 8. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.
    Eser OK; Ergin A; Tunçkanat F; Hasçelik G
    New Microbiol; 2008 Oct; 31(4):535-42. PubMed ID: 19123310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals.
    Al-Sweih NA; Al-Hubail MA; Rotimi VO
    J Chemother; 2011 Feb; 23(1):13-6. PubMed ID: 21482488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
    Liou BH; Lee YT; Kuo SC; Liu PY; Fung CP
    Antimicrob Agents Chemother; 2015; 59(6):3637-40. PubMed ID: 25824230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.
    Nix DE; Matthias KR
    J Antimicrob Chemother; 2010 Jun; 65(6):1311-2. PubMed ID: 20378673
    [No Abstract]   [Full Text] [Related]  

  • 13. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis.
    Tutuncu EE; Kuscu F; Gurbuz Y; Ozturk B; Haykir A; Sencan I
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e224-6. PubMed ID: 19962335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patients.
    Kanık-Yüksek S; Tezer H; Ozkaya-Parlakay A; Gulhan B; Sayed-Oskovi H; Kara A; Şenel E
    Pediatr Infect Dis J; 2015 Jun; 34(6):677. PubMed ID: 25970113
    [No Abstract]   [Full Text] [Related]  

  • 16. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment of pan-resistant Acinetobacter baumannii infection of the lung with tigecycline: a report of one case].
    Shao BB; Feng HB
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Oct; 25(10):636. PubMed ID: 24119705
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-test minimum inhibitory concentrations for tigecycline against nosocomial Acinetobacter baumannii strains.
    Akcam FZ; Kaya O; Basoglu N; Avsar K; Yayli G
    J Chemother; 2007 Apr; 19(2):230-1. PubMed ID: 17434835
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of test methodology, media type and ion content on the susceptibility of Acinetobacter spp. to tigecycline.
    Qu J; Zong Z; Yu R; Hu T; Ye H; Lü X
    J Antimicrob Chemother; 2014 Jun; 69(6):1710-1. PubMed ID: 24481321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.